Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to reduce harmful side effects in rare cancer patients

NCT ID NCT07471425

Knowledge-focused Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 1,100 people with advanced neuroendocrine tumors (a rare, slow-growing cancer) to see which treatments or treatment sequences cause the fewest long-term side effects. Researchers will track patients for up to 5 years, recording any side effects that last more than 6 months. The goal is to create a tool that helps doctors choose the best treatment plan for each patient, balancing effectiveness with quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

unresectable or metastatic NET patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Unresectable local or metastatic NET naive of treatment tumor except somatostatin analogues or primary surgery. * Unresectable local or metastatic NET newly diagnosed\<6 months whatever the primary NET site * Well differentiated neuroendocrine tumor (WHO classifications) pathologically reviewed locally * No initial medical absolute contraindication to any of the authorized or recommended treatments (no AE\>grade 1 according to NCI CTC v.5 criteria), * Patient who have full medical follow-up in an expert center of the French ENDOCAN network for the management of their advanced neuroendocrine tumor * Patient not opposed to data collection in the on GTE databasis * Patient not opposed to participate in the clinical study Exclusion Criteria: * Patients with severe illness that contraindicates participation to any study * Age \<18 years old

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine (NE) tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine (NE) tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHM Marseille La Timone

    Marseille, 13005, France

  • APHP Beaujon

    Clichy, 92110, France

  • APHP Cochin

    Paris, 75014, France

  • CHRU Tours

    Tours, 37044, France

  • CHU Caen

    Caen, 14000, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, 63000, France

  • CHU Dijon

    Dijon, 21000, France

  • CHU Lille

    Lille, 59000, France

  • CHU Poitiers

    Poitiers, 86196, France

  • CHU Reims

    Reims, 51092, France

  • CHU Strasbourg

    Strasbourg, 67200, France

  • CHU Toulouse

    Toulouse, 31300, France

  • Centre Eugene Maquis

    Rennes, 35000, France

  • Hôpital Edouard Herriot

    Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.